Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.50M P/E - EPS this Y 55.40% Ern Qtrly Grth -
Income -10.22M Forward P/E -0.35 EPS next Y 43.90% 50D Avg Chg -21.00%
Sales - PEG -0.02 EPS past 5Y - 200D Avg Chg -57.00%
Dividend N/A Price/Book 1.04 EPS next 5Y 15.00% 52W High Chg -87.00%
Recommedations 2.30 Quick Ratio 3.59 Shares Outstanding 3.26M 52W Low Chg 19.00%
Insider Own 8.76% ROA -74.39% Shares Float 2.89M Beta 0.58
Inst Own 1.38% ROE -134.67% Shares Shorted/Prior 73.79K/104.81K Price 0.43
Gross Margin - Profit Margin - Avg. Volume 118,840 Target Price 43.00
Oper. Margin - Earnings Date Nov 11 Volume 160,312 Change 1.54%
About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Processa Pharmaceuticals, Inc. News
10/30/24 Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
10/02/24 Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
09/03/24 Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
08/28/24 Processa Pharmaceuticals Provides Product Pipeline and Financial Update
08/19/24 Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
07/30/24 Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
07/17/24 Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
06/11/24 Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
05/06/24 Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
04/30/24 Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
04/11/24 Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
04/07/24 Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k
03/28/24 Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
03/25/24 Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
08:15 AM Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
02/14/24 Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
02/06/24 Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
02/01/24 Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
01/26/24 Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
01/25/24 Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
PCSA Chatroom

User Image Haimalon Posted - 56 minutes from now

$PCSA So no one home 🏡

User Image 2jmoney Posted - 1 day ago

$PCSA ahhh here we are 1 year later under a buck, almost to what I predicted after r/s, same bs as other tickers r/s nails company out they hit offerings and within a year your back to where you were before. It’s not the companies scamming us it’s the SEC allowing them to play these cards. Send their as* to OTC. Make them regain compliance from there

User Image Haimalon Posted - 2 days ago

$PCSA I understand the sall but who is buying As it seem know management here , the price is dropping for month and no one cares ….

User Image PenkeTrading Posted - 5 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Processa Pharmaceuticals Inc. Is that bullish or bearish? $PCSA #Processa #RsiOversold #NASDAQ

User Image cfvk Posted - 6 days ago

$PCSA ruh roh, that large support bid got taken out bottom = ??

User Image Haimalon Posted - 1 week ago

$PCSA 🥺🥺🥺

User Image HemaFL24 Posted - 1 week ago

$PCSA $1.50 lets go 🚀🚀🚀

User Image Drillbig1 Posted - 2 weeks ago

$PCSA

User Image Haimalon Posted - 2 weeks ago

$PCSA Any guess where we go today ?

User Image longjohntrader Posted - 10/31/24

$PCSA the biggest loss in 25 years of trading

User Image Kokoblack Posted - 10/31/24

$PCSA $15k down I'm fuck

User Image longjohntrader Posted - 10/31/24

$PCSA no Money left. I m out

User Image Dave24689990 Posted - 10/31/24

$PCSA must be under 1m in cash at this point. wait till the financing to revisit.

User Image Jeffg1981 Posted - 10/30/24

$PCSA net loss of $3.4 million for the quarter and only $2.9 million cash on hand.

User Image geumrivale Posted - 1 month ago

@debbiekatz $PCSA low float seem loaded enough here.

User Image Americanbulls Posted - 1 month ago

$PCSA apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=PCSA

User Image cryptofollow2223 Posted - 1 month ago

$PCSA Who owns the asset? https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=TW192cA2H8XFRyYJrCcVFg==

User Image 2jmoney Posted - 1 month ago

$PCSA I’m a player again at .60 once we drop below a buck that .60 support will roll. It’s to hard to support bios and cancer products above a dollar their r/s offering game is to strong in the market

User Image Jeffg1981 Posted - 1 month ago

$PCSA doesn’t look like it

User Image Dave24689990 Posted - 1 month ago

$PCSA revisit after the financing. not sure how they are going to pay for the trial with their coffers almost empty.

User Image Drillbig1 Posted - 1 month ago

$PCSA Reverse split stocks seem to always make their way back home. Headed for 20 cents.

User Image Bader0555 Posted - 1 month ago

$PCSA next week above 2

User Image Dave24689990 Posted - 1 month ago

$PCSA read the details of that lawsuit. never a good thing when the licensor or your lead asset has demanded it back. two sides to every story but the counterclaims part is pretty interesting. beside that, they look completely out of cash. will be fun to watch from the sidelines. glta

User Image Sam630 Posted - 1 month ago

$PCSA is on the right track and has successfully initiated its Phase 2 trial on time. It dosed the first patient on October 2, 2024, avoiding the risk of losing the asset. Here’s a summary of the lawsuit by ChatGPT 👇🏻 it’s about time of this to rocket

User Image Jeffg1981 Posted - 1 month ago

$PCSA hard to see this turning around…

User Image moneymarker20188 Posted - 1 month ago

$PCSA green eod and tomorrow

User Image cryptofollow2223 Posted - 1 month ago

$PCSA Not sure they will even own asset after this lawsuit https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=TW192cA2H8XFRyYJrCcVFg==

User Image Tradefordaddy Posted - 1 month ago

$PCSA green

User Image doublenickels55 Posted - 1 month ago

$PCSA Eff this mother effing piece of dog crap.

User Image Dave24689990 Posted - 1 month ago

$PCSA checked the balance sheet, on fumes. now i understand all the selling on the news.

Analyst Ratings
HC Wainwright & Co. Buy Aug 20, 24
HC Wainwright & Co. Buy Aug 19, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 12, 24
HC Wainwright & Co. Buy May 13, 24
HC Wainwright & Co. Buy Apr 25, 24
Benchmark Speculative Buy Mar 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lin Patrick Chief Business - Str.. Chief Business - Strategy Off Jan 31 Buy 2.39 4,000 9,560 27,478 02/01/24
Ng George K Chief Executive Offi.. Chief Executive Officer Jan 30 Buy 2.7 10,000 27,000 20,000 01/31/24
Young David President & CEO President & CEO Apr 14 Buy 0.5499 20,000 10,998 430,424 04/14/23
Young David President & CEO President & CEO Apr 11 Buy 0.48 60,000 28,800 410,424 04/13/23
Lin Patrick Chief Business - Str.. Chief Business - Strategy Off May 17 Buy 1.5945 2,000 3,189 433,390 05/19/22
Lin Patrick Chief Business - Str.. Chief Business - Strategy Off Apr 06 Buy 3.34 2,000 6,680 431,390 04/08/22
Yorke Justin W Director Director Jan 27 Sell 3.30 1,854 6,118 532,563 01/31/22